GSK Opens Singapore Plant To Produce Pneumonia Vaccines
This article was originally published in PharmAsia News
Executive SummaryU.K.-based GlaxoSmithKline plans to produce vaccines in Singapore to prevent bacteria that cause pneumonia. The plans were announced at an opening of a $411 million Singapore plant, which is to be tested for up to two years before beginning vaccine production in 2011. The intent is to produce pneumococcal conjugate vaccine for children under 2 years old. GSK introduced the vaccine in the United States in 2000 and it has since shown to be effective in reducing the number of pneumococcal cases in children. (Click here for more
You may also be interested in...
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.
Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.
Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.